Gland Pharma faces Rs 3.53 crore customs IGST demand and equal penalty

Regulatory & Legal View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.8%Reaction day

₹2546.10

prior close

₹2529.40

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.6%-3.2% vs market

Pharmaceuticals peers, median of 166sector-1.0%-2.8% vs sector

On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-1.1

15m

-1.2

30m

-1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.8-0.6-3.2-1.0-2.8

Next day

-3.5-0.5-3.0-0.3-3.2

-2.4-0.0-2.4-0.3-2.1

-4.2-1.4-2.8-1.5-2.7

-6.2-2.5-3.7-2.3-3.9

-6.2-2.8-3.4-1.9-4.3

-4.4-2.0-2.4-2.6-1.8

15d

+1.4+1.4+0.0-0.4+1.8

+14.0+1.1+12.9-0.5+14.5

+14.1-0.6+14.6-0.3+14.4

+19.0-3.7+22.7-4.3+23.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gland Pharma received a customs order dated July 10, 2026, confirming an IGST demand of Rs 3.53 crore plus interest, along with an equal Rs 3.53 crore penalty for FY 2020-21 and FY 2021-22. Total disputed exposure is about Rs 7.06 crore. The company says the demand is not justified and will file an appeal. Company states no material impact on financials or operations.

Likely market impact

Disputed tax demand of about Rs 7.06 crore (demand plus penalty). Company plans to appeal and says impact is not material.